ArticleCell death discovery2025
O-GlcNAc transferase influences the progression of degenerative cartilage disease in lumbar facet joint osteoarthritis through FoxO1 and EGR1.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- OGT regulates histone demethylation and alleviates osteoarthritis progression by O-GlcNAcylation of KDM6B.Journal of advanced research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the role of the O-GlcNAc transferase (OGT)/Forkhead Box O1 (FoxO1) signaling axis in age-induced facet joint osteoarthritis (FJOA) and its impact on chondrocyte homeostasis. Using a mouse model, the effects of OGT knockout on cartilage integrity in facet joints were examined. Molecular assays were conducted to analyze OGT's influence on FoxO1 expression and its stability against ubiquitin-mediated degradation. In vitro studies with chondrocytes were performed to assess the impact of FoxO1 overexpression on extracellular matrix synthesis, while in vivo experiments were carried out to test the protective effects of FoxO1 overexpression on FJOA progression. Additionally, the functionality of ATDC5 cells and the regulation of EGR1 by the OGT/FoxO1 axis were evaluated. OGT knockout led to exacerbated cartilage degeneration in facet joints, promoting age-related FJOA. OGT was found to stabilize FoxO1 protein by amplifying its expression and preventing its degradation. The T627 site on FoxO1, along with other key sites (T317, S550, T648, S654), was identified as essential for FoxO1's stability and transcriptional activity upon OGT overexpression. Elevated FoxO1 levels counteracted OGT deficiency in chondrocytes, enhancing extracellular matrix synthesis. In vivo, FoxO1 overexpression mitigated FJOA progression and chondrocyte apoptosis due to OGT deficiency. The OGT/FoxO1 signaling also regulated EGR1 expression, impacting ATDC5 cell function. Collectively, the OGT/FoxO1/EGR1 axis plays a critical role in maintaining chondrocyte homeostasis and protecting facet joint integrity, suggesting a potential therapeutic target for age-related FJOA and cartilage degeneration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.